AstraZeneca's Seroquel XR refused EU approval for major depression
This article was originally published in Scrip
Executive Summary
The Netherlands regulatory agency, the MEB, has rejected AstraZeneca's supplemental marketing application under the mutual recognition procedure for its atypical antipsychotic Seroquel XR (quetiapine fumarate extended-release) in the treatment of major depressive disorder.